EGFR and non-small cell lung carcinoma: Patients with advanced NSCLC resistant to EGFR-TKIs were randomly divided into chemotherapy group (docetaxel or pemetrexed with or without cisplatin/carboplatin), EGFR-TKIs group and Yiqi Yangyin Sanjie Decoction + EGFR-TKIs group.